Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $159.90 | 7 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boston Scientific Corporation | $46.58 | 2 | $0 (2024) |
| Allergan Inc. | $44.69 | 3 | $0 (2017) |
| Astellas Pharma US Inc | $43.15 | 1 | $0 (2024) |
| AbbVie Inc. | $25.48 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $67.21 | 2 | Astellas Pharma US Inc ($43.15) |
| 2023 | $25.48 | 1 | AbbVie Inc. ($25.48) |
| 2020 | $22.52 | 1 | Boston Scientific Corporation ($22.52) |
| 2017 | $44.69 | 3 | Allergan Inc. ($44.69) |
All Payment Transactions
7 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/04/2024 | Boston Scientific Corporation | Moses 550 DFL (Device) | Food and Beverage | In-kind items and services | $24.06 | General |
| Category: Moses 550 DFL_URO | ||||||
| 07/30/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $43.15 | General |
| Category: Oncology | ||||||
| 11/08/2023 | AbbVie Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $25.48 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 01/09/2020 | Boston Scientific Corporation | REZUM (Device) | Food and Beverage | In-kind items and services | $22.52 | General |
| Category: PROSTATE HEALTH | ||||||
| 04/05/2017 | Allergan Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/28/2017 | Allergan Inc. | NAMENDA XR (Drug) | Food and Beverage | In-kind items and services | $12.92 | General |
| Category: NEUROSCIENCE | ||||||
| 01/26/2017 | Allergan Inc. | VIBERZI (Drug) | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: GASTROENTEROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 1 | 28 | 29 | $2,867 | $819.00 |
All Medicare Procedures & Services
1 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 28 | 29 | $2,867 | $819.00 | 28.6% |
About Dr. Mark Douglas, M.D
Dr. Mark Douglas, M.D is a Emergency Medical Services healthcare provider based in Biddeford, Maine. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1326050410.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Douglas, M.D has received a total of $159.90 in payments from pharmaceutical and medical device companies, with $67.21 received in 2024. These payments were reported across 7 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($159.90).
As a Medicare-enrolled provider, Douglas has provided services to 28 Medicare beneficiaries, totaling 29 services with total Medicare billing of $819.00. Data is available for 1 year (2020–2020), covering 1 distinct procedure/service records.
Practice Information
- Specialty Emergency Medical Services
- Other Specialties Emergency Medical Services
- Location Biddeford, ME
- Active Since 08/13/2006
- Last Updated 07/02/2014
- Taxonomy Code 207PE0004X
- Entity Type Individual
- NPI Number 1326050410
Products in Payments
- Xtandi (Drug) $43.15
- BOTOX (Biological) $25.48
- Moses 550 DFL (Device) $24.06
- REZUM (Device) $22.52
- VIBERZI (Drug) $17.44
- LINZESS (Drug) $14.33
- NAMENDA XR (Drug) $12.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.